Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5

NCT02228655 is registered in ClinicalTrials.gov with FerruMax Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02228655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2014
Completion date
July 31, 2015
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia in chronic kidney disease